Released: September 6, 2017

Defense Health Program
Department of Defense Kidney Cancer Research Program
Funding Opportunities for Fiscal Year 2017

The FY17 Defense Appropriations Act provides $10 million (M) to the Department of Defense Kidney Cancer Research Program (KCRP) to support United States Army Medical Research Acquisition Activity (USAMRAA). As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA) J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

The KCRP is providing the information in this pre-announcement to allow investigators time to plan and develop applications. FY17 KCRP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on the website in October 2017. Pre-application (Letter of Intent) and application deadlines will be available when the Program Announcements are released. This pre-announcement should not be construed as an obligation by the government.

Award Mechanism Eligibility Key Mechanism Elements Funding
Consortium Development Award Investigators at or above Assistant Professor (or equivalent)
  • Supports infrastructure development to establish the necessary collaborations among a Coordinating Center and Clinical Sites
  • Multi-institution collaboration required
  • Supports clinical trials of novel interventions with the potential to have a significant impact on patient care in kidney cancer
  • Proposed trials may be Phase 0, Phase 1, or Phase 2
  • Minimum of three separate institutes: one Coordinating Center and at least two Clinical Sites (other than the Coordinating Center)
  • Awardee will be eligible to apply for FY19 Consortium Award, if funds are available
  • Maximum funding of $1.6 million total costs
  • Maximum period of performance is 2 years
Idea Development Award Established Investigators:
Independent investigators at or above the level of Assistant Professor (or equivalent) and 10 years or more from a terminal degree; or
Early Career Investigators:
Investigators at the level of Assistant Professor, Instructor, or Assistant Research Professor (or equivalent) and less than 10 years from a terminal degree (excluding time spent in medical residency or family medical leave) at the time of application submission deadline are eligible.
  • Supports new ideas that represent innovative, high-risk/high-gain approaches to kidney cancer research, and have the potential to make an important contribution to kidney cancer.
  • Preliminary data is required; need not be in kidney cancer.
  • Innovation and Impact are the most important review criteria.
  • Clinical Trials are not allowed
  • Areas of Interest include:
    Microenvironment, Metabolism, Chromatin and Gene Regulation, Rare Cancers, Screening, Early Detection, Novel Imaging Technologies, Liquid Biopsy, Biomarker Development, Prognosis, Targeted Therapies, Immunotherapies, Resistance, Novel Interventions, Surgical, Ablation, Radiation, Prognosis, Managing Toxicity, Survivorship and Patient Experience, Surveillance, Genetic Risk Factors
  • Maximum funding of $400,000 in direct costs (plus indirect costs)
  • Period of performance not to exceed 3 years
Concept Award Investigators at all academic levels
  • Supports highly innovative, untested, potentially groundbreaking concepts in kidney cancer
  • Emphasis on innovation
  • Clinical trials not allowed
  • Preliminary data not allowed
  • Blinded review
  • Maximum funding of $75,000 for direct costs (plus indirect costs)
  • Maximum period of performance is 1 year
Translational Research Partnership Investigators at or above the level of Assistant Professor (or equivalent)
  • Supports partnerships between clinicians and laboratory scientists that accelerate ideas in kidney cancer into clinical applications
  • Supports translational correlative studies
  • Preliminary data required
  • Funding for clinical trials not allowed
  • Maximum funding of $600,000 for direct costs (plus indirect costs)
  • Maximum period of performance is 3 years

A pre-application (letter of intent) is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at prior to the pre-application (letter of intent) deadline. All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the website. The application package containing the required forms for each award mechanism will also be found on A listing of all CDMRP funding opportunities can be obtained on the website by performing a basic search using CFDA Number 12.420.

Applications must be submitted through the Federal Government’s single-entry portal, Submission deadlines are not available until the Program Announcements are released. For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at For more information about the KCRP or other CDMRP-administered programs, please visit the CDMRP website (

Point of Contact:

CDMRP Public Affairs

Last updated Thursday, May 26, 2022